News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bio-Rad Laboratories, Inc. (BIO) Reports Second-Quarter 2014 Financial Results



8/7/2014 10:12:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HERCULES, CA--(Marketwired - August 05, 2014) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2014.

Second-quarter reported revenues were $536.8 million, up 2.2 percent compared to $525.3 million reported for the second quarter of 2013. On a currency-neutral basis, quarterly revenues increased 1.1 percent compared to the same period last year. Second-quarter gross margin was 55.4 percent compared to 57.1 percent reported during the same quarter in 2013. The net decline in gross margin is largely attributable to product mix and continued pricing pressures in the diagnostics market.

Net income for the second quarter of 2014 was $31.6 million, or $1.09 per share on a fully diluted basis, compared to $34.6 million, or $1.20 per share, respectively, during the same period last year.

On a reported basis, year-to-date revenues were up 2.1 percent to $1.05 billion compared to $1.02 billion for the first two quarters of 2013. On a currency-neutral basis, revenues grew 2.0 percent.

Year-to-date net income for 2014 was $38.3 million, or $1.32 per share on a fully diluted basis, compared to $54.8 million, or $1.90 per share, respectively, during the same period in 2013.

The lower net income for the first half of 2014 when compared to the same period last year, was primarily driven by lower gross margins, higher SG&A that includes a $9.8 million accrual in the first quarter resulting from the Company's efforts to resolve the previously disclosed investigation of the Company in connection with the United States Foreign Corrupt Practices Act, and an increase in R&D expense as a result of our current quarter acquisition of GnuBIO, Inc. In contrast to the first half of 2013, the tax rate for the first six months of 2014 is higher as it did not include a benefit of the U.S. research & development tax credit. Cash flow was strong for the six months ended June 30, 2014 compared to the same period last year, as cash provided by operations was $149.8 million in 2014 versus $43.8 million last year. This strength was largely due to an increase in customer collections, as well as a decrease in interest paid in the first half of 2014 related to the redemption of Senior Subordinated Notes in 2013.

"Although we continued to see softness in some markets during the second quarter, we are encouraged by an increase in sales in many parts of the world," said Norman Schwartz, Bio-Rad Chief Executive Officer. "As the year continues, we will remain focused on new products and systems that will help us grow our business."

Life Science
Life Science segment net sales for the second quarter of 2014 were $170.3 million, essentially flat, when compared to the same period last year. On a currency-neutral basis, Life Science segment net sales decreased by 1.1 percent compared to the same quarter last year. Although sales increased in both Europe and the U.S. during the second quarter of 2014, the timing of orders in Asia, most notably in China, had a negative impact on results compared to the second quarter of 2013. This performance was somewhat offset by growth of the Company's Droplet Digital™ PCR, process chromatography, and cell biology products.

Clinical Diagnostics
Reported net sales for the Clinical Diagnostics segment in the second quarter of 2014 were $362.9 million, up 3.2 percent compared to the same quarter last year. On a currency-neutral basis, net sales increased 2.1 percent. While sales increased in China and emerging markets in the second quarter of 2014, this was partially offset by a decline in Europe. During the quarter, Bio-Rad announced the launch of two new kits for its fully-automated BioPlex® 2200 system: the BioPlex® HIVAg-Ab kit, a first-in-class 5th generation HIV test, and the BioPlex® Vitamin D kit. Both kits were launched in markets outside the U.S.

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) August 5, 2014. Interested parties may access the call by dialing 866-318-8617 (in the U.S.) or 617-399-5136 (international), passcode: 33283045.

A live webcast of the conference call may be accessed in the Investor Relations section of www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), passcode: 48074970, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site and may be accessed in the Investor Relations section.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Income (in thousands, except per share data) (UNAUDITED) Three Months Ended Six Months Ended June 30, June 30, ---------------------- ---------------------- 2014 2013 2014 2013 ---------- ---------- ---------- ---------- Net sales $ 536,832 $ 525,321 $1,046,176 $1,024,993 Cost of goods sold 239,590 225,220 473,645 453,480 ---------- ---------- ---------- ---------- Gross profit 297,242 300,101 572,531 571,513 Selling, general and administrative expense 195,838 195,331 398,113 381,248 Research and development expense 55,717 51,841 108,260 102,184 ---------- ---------- ---------- ---------- Income from operations 45,687 52,929 66,158 88,081 Interest expense 5,564 11,664 9,421 22,641 Foreign currency exchange (gains) losses, net (286) 865 2,451 2,393 Other (income) expense, net (8,388) (8,644) (9,049) (10,044) ---------- ---------- ---------- ---------- Income before income taxes 48,797 49,044 63,335 73,091 Provision for income taxes (17,166) (14,442) (25,036) (18,317) ---------- ---------- ---------- ---------- Net income including noncontrolling interests 31,631 34,602 38,299 54,774 Net income attributable to noncontrolling interests - - - (21) ---------- ---------- ---------- ---------- Net income attributable to Bio-Rad $ 31,631 $ 34,602 $ 38,299 $ 54,753 ========== ========== ========== ========== Basic earnings per share: Net income per basic share attributable to Bio-Rad $ 1.10 $ 1.21 $ 1.33 $ 1.92 ========== ========== ========== ========== Weighted average common shares - basic 28,826 28,538 28,809 28,516 ========== ========== ========== ========== Diluted earnings per share: Net income per diluted share attributable to Bio- Rad $ 1.09 $ 1.20 $ 1.32 $ 1.90 ========== ========== ========== ========== Weighted average common shares - diluted 29,092 28,868 29,076 28,843 ========== ========== ========== ========== Bio-Rad Laboratories, Inc. Condensed Consolidated Balance Sheets (In thousands) June 30, December 31, 2014 2013 ------------ ------------ (UNAUDITED) Current assets: Cash and cash equivalents $ 384,670 $ 331,551 Short-term investments 262,908 277,369 Accounts receivable, net 378,891 422,660 Inventories, net 520,642 501,291 Other current assets 220,383 214,985 ------------ ------------ Total current assets 1,767,494 1,747,856 Property, plant and equipment, net 440,326 429,355 Goodwill, net 535,223 517,770 Purchased intangibles, net 292,547 266,188 Other assets 432,161 427,621 ------------ ------------ Total assets $ 3,467,751 $ 3,388,790 ============ ============ Current liabilities: Accounts payable $ 125,461 $ 148,510 Accrued payroll and employee benefits 134,905 130,658 Notes payable and current maturities of long- term debt 1,725 1,786 Income taxes payable and deferred tax liabilities 28,264 20,948 Other current liabilities 189,893 185,570 ------------ ------------ Total current liabilities 480,248 487,472 Long-term debt, net of current maturities 435,607 435,615 Other long-term liabilities 301,952 278,981 ------------ ------------ Total liabilities 1,217,807 1,202,068 ------------ ------------ Total stockholders' equity 2,249,944 2,186,722 ------------ ------------ Total liabilities and stockholders' equity $ 3,467,751 $ 3,388,790 ============ ============ Bio-Rad Laboratories, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (UNAUDITED) Six Months Ended June 30, 2014 2013 ------------ ------------ Cash flows from operating activities: Cash received from customers $ 1,087,487 $ 1,006,345 Cash paid to suppliers and employees (918,152) (911,227) Interest paid (10,912) (24,681) Income tax payments (17,059) (42,102) Other operating activities 8,460 15,419 ------------ ------------ Net cash provided by operating activities 149,824 43,754 Cash flows from investing activities: Payments for acquisitions and long-term investments (42,010) (65,883) Other investing activities (59,928) (68,683) ------------ ------------ Net cash used in investing activities (101,938) (134,566) Cash flows from financing activities: Payments on long-term borrowings (118) (123) Other financing activities 6,416 (6,013) ------------ ------------ Net cash provided by (used in) financing activities 6,298 (6,136) Effect of foreign exchange rate changes on cash (1,065) 559 ------------ ------------ Net increase (decrease) in cash and cash equivalents 53,119 (96,389) Cash and cash equivalents at beginning of period 331,551 463,388 ------------ ------------ Cash and cash equivalents at end of period $ 384,670 $ 366,999 ============ ============ Reconciliation of net income including noncontrolling interests to net cash provided by operating activities: Net income including noncontrolling interests $ 38,299 $ 54,774 Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities: Depreciation and amortization 73,007 68,211 Changes in working capital 38,045 (90,568) Other 473 11,337 ------------ ------------ Net cash provided by operating activities $ 149,824 $ 43,754 ============ ============


Investor and Financial Contacts:
Bio-Rad Laboratories, Inc.
Christine Tsingos
Executive Vice President and Chief Financial Officer
Ron Hutton
Vice President, Treasurer
510-724-7000
Email Contact



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES